Rapport Therapeutics (NASDAQ:RAPP) Director John Maraganore Acquires 9,411 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director John Maraganore acquired 9,411 shares of the business’s stock in a transaction that occurred on Thursday, October 22nd. The shares were acquired at an average cost of $26.45 per share, with a total value of $248,920.95. Following the completion of the transaction, the director directly owned 9,411 shares in the company, valued at approximately $248,920.95. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Rapport Therapeutics Trading Up 5.9%

RAPP traded up $1.47 on Thursday, hitting $26.53. The company had a trading volume of 1,453,606 shares, compared to its average volume of 407,078. The firm has a market cap of $1.27 billion, a P/E ratio of -8.73 and a beta of 1.22. Rapport Therapeutics, Inc. has a 1 year low of $23.75 and a 1 year high of $52.93. The company’s fifty day moving average price is $39.86 and its 200 day moving average price is $39.07.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, analysts predict that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Institutional Investors Weigh In On Rapport Therapeutics

Several large investors have recently added to or reduced their stakes in the business. TRV GP V LLC purchased a new position in Rapport Therapeutics in the 2nd quarter valued at approximately $261,709,477. ARCH Venture Management LLC purchased a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $155,376,512. BlackRock Inc. acquired a new stake in Rapport Therapeutics in the second quarter valued at approximately $112,500,000. Johnson & Johnson acquired a new stake in Rapport Therapeutics in the second quarter valued at approximately $74,360,823. Finally, TRV GP VI LLC acquired a new stake in Rapport Therapeutics in the second quarter valued at approximately $40,387,314.

Key Stories Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 is advancing to Phase 3. Rapport said the drug met both Phase 2 endpoints in bipolar mania, producing statistically significant placebo-adjusted improvements in manic symptoms and overall illness severity. The results strengthen the potential value of RAP-219 and expand its development opportunity beyond epilepsy. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts continue to raise or maintain bullish targets. JonesTrading increased its price target from $50 to $82 and maintained a Buy rating. BTIG Research also raised its target, while HC Wainwright reaffirmed its Buy rating. Raymond James recently set an $86 target and maintained Strong Buy. The analyst activity suggests Wall Street sees substantial upside if RAP-219 succeeds in later-stage development. BTIG Research price target update HC Wainwright rating update
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares for $143,550. The purchase increased his direct holdings by 55% to 15,500 shares, a potentially supportive signal of management confidence. SEC insider ownership filing
• Neutral Sentiment: The clinical results move RAP-219 toward Phase 3 but do not eliminate biotechnology risks, including trial execution, regulatory approval, funding needs, and eventual commercialization.
• Negative Sentiment: Some coverage characterized the trial outcome as narrower than investors initially hoped. Rapport also remains unprofitable, recently reporting quarterly EPS below consensus, which could limit gains if future clinical or financial results disappoint. Rapport bipolar data analysis

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on RAPP shares. BTIG Research upped their price objective on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the stock a “buy” rating in a report on Tuesday. Raymond James Financial reiterated a “strong-buy” rating and issued a $86.00 target price on shares of Rapport Therapeutics in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, October 15th. Citigroup reissued an “outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday. Finally, Leerink Partners started coverage on Rapport Therapeutics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.